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Li-Fraumeni Syndrome (LFS) is a rare autosomal 
dominant disorder characterized by germline mutations 
in TP53 and the early onset of multiple forms of cancer, 
including breast cancer [1,2]. As predicted by the 
Knudsen two-hit hypothesis, mutation or inactivation of 
one allele results in somatic inactivation of the second 
allele, ie. loss of heterozygosity [3]; however, one-hit 
effects without LOH can also account for an increased 
growth advantage and tumorigenicity [4]. The National 
Comprehensive Cancer Network (NCCN) provides 
guideline recommendations for screening LFS family 
members to aid early detection of tumors. However, 
many LFS families remain undiagnosed as a result of a 
lack of atypical histopathological presentations that can 
be used to identify these families. Additionally, diagnosis 
is complicated by the fact that almost all LFS-associated 
TP53 mutations are missense, which often make clinicians 
reluctant to make a diagnosis of LFS due to the inherent 
ambiguity of classifying missense variants. Therefore, 
better molecular diagnostics for LFS family members 
are  needed  so  that  they  can  benefit  from  screening. 
Because TP53 mutations are among the most common 
in all tumors, LFS diagnostics have great potential to be 
applied to early detection of sporadic tumors in patients 
whose tumors acquire somatic TP53 mutations. Herbert 
et al. now report differences in the molecular signature 
associated with two breast epithelial and stromal cell lines 
derived from LFS patients with different TP53 mutations. 
They assess differences between these two LFS genotypes 
and normal control tissue by gene array analysis, and 
compare the relative sensitivity of target genes to TP53-
modifying drugs. 
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Figure 1: Survival pathways associated with the Li-Fraumeni mutated TP53 phenotype. Li-Fraumeni Syndrome 
(LFS) breast epithelial cells heterozygous for TP53 mutation M133T exhibit a marked upregulation of BIRC3 expression.  BIRC3 
associates with the TNFα receptor 2 (TNFR2)-associated proteins, TRAF1 and TRAF2, to inhibit caspase-3 activation and block 
apoptosis. Additionally, TRAF1/2 upregulates expression of transcription factor NFκB, which in turn increases BIRC3 expression. 
LFS stromal cells exhibit upregulation of IL-1β, which induces NFκB, and the secretion of cytokines that further perpetuate NFκB 
expression and pro-survival signaling.Oncotarget 2010; 1:  470 - 471 471 www.impactjournals.com/oncotarget
Herbert  et al. demonstrate that breast epithelial 
cells with the TP53 M133T mutation (LFS-50) exhibit 
a marked increase (20-40-fold) in expression of the 
antiapoptotic gene, BIRC3, as well as an increase in IL-1β 
gene expression in stromal cells. This contrasts with little 
or no changes in the expression of these genes in epithelial 
and stromal cells (LFS-IUSM) derived from a patient 
with the frameshift mutation. This remarkable difference 
suggests that cells heterozygous for mutated TP53, in 
contrast to those expressing wild-type TP53, may have a 
survival advantage. BIRC3 associates with the TNFR2-
associated factor, TRAF2, which mediates inhibition of 
caspase-3 [5] (Fig. 1). TRAF2 also promotes increased 
NFκB expression, a transcription factor that upregulates 
BIRC3 expression [6]. Since stromal cells associated with 
the mutated TP53 phenotype exhibit elevated expression 
of IL-1β, which also activates NFκB signaling and the 
expression  of  inflammatory  cytokines,  this  suggests 
a scenario, whereby cytokine secretion by adjacent 
stromal cells can exacerbate the antiapoptotic signaling 
pathway in epithelial cells (Fig. 1). Interestingly, the high 
frequency of osteosarcomas in heterozygous TP53 mice 
[7], as in LFS patients [2], exhibit a similar increase in 
Birc3 gene expression, and a dependency on this gene for 
tumor growth.
Herbert et al. also provide a basis for a therapeutic 
approach that may selectively inhibit tumors in LFS 
patients expressing the mutated TP53 phenotype. 
Treatment of LPS-50 cells with both CP-31398 and 
PRIMA-1, drugs believed to interrupt signaling by mutated 
TP53 and convert the mutated TP53 conformation to the 
wild-type conformation [8,9], produced a synergistic 
inhibitory effect on BIRC3 expression, and a reduction 
in cell growth. These results imply that therapy targeting 
mutated TP53 may selectively induce apoptosis in tumors 
from patients with this genotype. These studies also 
suggest that patients with the inflammatory gene signature 
in  stromal  tissue  may  derive  additional  benefit  from 
treatment with anti-inflammatory therapy to interrupt the 
feed forward pro-survival cycle induced by mutated TP53.  
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